Hikma Pharmaceuticals Public annual net income
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Net Income Growth & History (HIK)
Hikma Pharmaceuticals Public's net income was $407.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $407.0M | $45.0M | +12.43% |
| 2024 | 2024-12-31 | $362.0M | $170.0M | +88.54% |
| 2023 | 2023-12-31 | $192.0M | $1.0M | +0.52% |
| 2022 | 2022-12-31 | $191.0M | −$229.0M | −54.52% |
| 2021 | 2021-12-31 | $420.0M | −$10.0M | −2.33% |
| 2020 | 2020-12-31 | $430.0M | — | — |
Hikma Pharmaceuticals Public net income trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's net income decreased from $430.0M to $407.0M, a change of −$23.0M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company official filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...